Immutep Quarterly Activities Report Q3 FY25

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Immutep Quarterly Activities Report Q2 FY25

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Patient Enrolment Completed for INSIGHT-003